Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Pfizer on Acquisition of CovX


NEW YORK, NY, December 18, 2007 — Pfizer Inc. announced today that it has entered into an agreement to acquire CovX, a privately-held biotherapeutics company. Covington & Burling LLP advised Pfizer on the transaction.

Pfizer, the world’s largest research-based biomedical and pharmaceutical company, discovers and develops innovative medicines to treat and help prevent disease for both people and animals. CovX specializes in preclinical oncology and metabolic research. Its biotherapeutics technology platform is expected to further enhance Pfizer’s biologic portfolio.

The Covington corporate team was led by New York-based partner J. D. Weinberg and included associates Andrew Muratore, Noa Rosenberg-Segalovitz, and Jonathan Mukai. The New York, San Francisco, and Washington-based team also included partners Jim Snipes and Peter Safir and associates Chelsea Tanaka-Delgado and Susan Lee (life sciences) and partner Michael Francese and associate Kendra Roberson (employee benefits).

Share this article: